F11R and cancer: JAM-A was initially identified on platelets and later on endothelial and epithelial cells [16, 17] and has been associated with different functions like monocyte/leukocyte transmigration [10, 17–19], but its function in cancer remains unclear, as both high and low expression levels have been associated with poor prognosis.